Answers are grounded in this paper and cite their sources.
Aims Resmetirom and semaglutide 2.4 mg are approved for metabolic dysfunction‐associated steatohepatitis but have not been tested together. We examined recorded incretin exposure among resmetirom initiators and the frequency and correlates of co‐initiation. Materials and Methods This new‐user cohort study used TriNetX US Collaborative Network health records of patients first prescribed resmetirom from 14 March 2024 to 16 July 2026. Among patients without incretin prescriptions in the prior 5 years, those with an incretin prescription 0–30 days after resmetirom (co‐initiators) were compared with non‐co‐initiators using standardized mean differences (SMDs) and Mantel–Haenszel analysis stratified by overweight/obesity and Type 2 diabetes. Results Of 6837 initiators, 76.6% had overweight/obesity (code or body mass index [BMI] ≥ 30 kg/m 2 ), 44.0% Type 2 diabetes and 16.8% a cirrhosis code. An incretin prescription was recorded in 37.2%, mostly before resmetirom (33.8%; excluded from the comparison). Of the remaining 4524, 231 (5.1%) were co‐initiators. Coded overweight/obesity (49.4% vs. 49.0%; SMD: 0.01) and Type 2 diabetes (30.3% vs. 33.1%; SMD: 0.06) were similar; co‐initiation was about 5% in every stratum (Mantel–Haenszel odds ratios: overweight/obesity 1.08 [95% CI: 0.80–1.46]; diabetes 1.00 [0.75–1.34]). Co‐initiators had higher mean BMI (35.3 vs. 33.0 kg/m 2 ; SMD: 0.33) and were more often prescribed metformin (27.7% vs. 19.0%; SMD: 0.21). Conclusions Because more than one‐third of resmetirom initiators had a recorded incretin prescription, mostly before initiation, trials of combined treatment are needed. Co‐initiation was uncommon and not clearly associated with overweight/obesity or Type 2 diabetes, despite higher BMI in co‐initiators.
No takes yet. Share an insight, caveat, or question.
Papadimopoulos et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: